Sai Life Sciences stock rating upgraded to Buy at Jefferies on capacity expansion plans

Jefferies upgraded Sai Life Sciences Ltd (SAILIFE:IN) to Buy from Hold, raising its price target to INR1,000.00 from INR800.00, following the company's strong first-quarter results. The upgrade is attributed to robust performance across its Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) segments, coupled with plans to nearly double manufacturing capacity over the next 18 months due to strong order visibility. Jefferies noted Sai Life Sciences offers superior near-term growth visibility compared to peers facing destocking, leading to a 1-3% increase in its FY26-28E EBITDA estimates.

Analysis

Jefferies has upgraded Sai Life Sciences Ltd (SAILIFE:IN) to Buy from Hold, concurrently raising its price target to INR 1,000.00 from INR 800.00. This revision is predicated on the company's first-quarter results, which delivered an 'all-around beat' with notable strength in both its Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) segments. Critically, Sai Life Sciences is embarking on a significant capacity expansion, aiming to nearly double its manufacturing capabilities over the next 18 months, a move supported by strong order visibility and the scale-up of existing projects. This positions the company favorably against peers in the Indian CDRMO space, many of whom are currently navigating destocking challenges. The strong operational performance and clear growth pipeline have led Jefferies to increase its FY26-28E EBITDA estimates for the company by 1-3%, signaling heightened confidence in its medium-term earnings trajectory.

Key Decisions for Investors

• The combination of a strong earnings beat, a significant analyst upgrade, and a clear capacity expansion plan presents a strong bullish case for the stock.
• Investors should consider Sai Life Sciences as a potential outperformer within the Indian CDRMO sector, given its superior near-term growth visibility while competitors face destocking headwinds.
• Monitor the execution of the manufacturing capacity expansion over the next 18 months, as successful implementation is key to realizing the projected EBITDA growth and validating the current investment thesis.